• Contact/
  • Home/

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • About
  • Team
  • Portfolio
  • Exit History
  • News

  • Advent Life Sciences
  • Advent Life Sciences

Page 8 of 24

 
<< Start < Prev 3 4 5 6 7 8 9 10 11 12Next >End >>
08.04.2020Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform

Press Release

07.04.2020Amphista Therapeutics raises $7.5m Series A round to advance targeted protein degradation assets in cancer

Press Release

18.02.2020 New company takes aim at treatments for multiple sclerosis

Press Release

13.01.2020KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814

Press Release

22.12.2019Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration with MSD Phase II Trial

Press Release

14.11.2019Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

Press Release

11.11.2019F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

 

Press Release

09.09.2019Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System

 

Press Release

26.04.2019Acutus Medical’s New Contact Mapping Software Receives CE Mark

 

Press Release

18.04.2019Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA

Press Release



  • Privacy Policy
  • Legal and Regulatory Matters

©2022 Advent Life Sciences